Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

A Maryland man with diabetes is suing Novo Nordisk, alleging that semaglutide ... heart failure, or chronic kidney disease patients on renin-angiotensin-aldosterone system (RAAS) inhibitors ...

Related FDA warns of fake Ozempic Type 2 diabetes injection drugs Evidence grows that Ozempic can curb alcoholism GLP-1 medications show promise in slowing kidney disease progression MASH occurs ...

In his suit, Todd Engel, of Howard County, accused Novo Nordisk Inc. and 10 other ... for the treatment of diabetes and chronic kidney disease. However, it is often prescribed or used for weight ...

In more recent news, FDA has approved Ozempic to reduce risk of kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Novo Nordisk also has introduced ...

By Dani Blum I’ve reported on Ozempic since 2022. New research shows that semaglutide, the compound in the weight-loss drug Wegovy, could treat an increasingly common liver disease. The study ...